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Abstract 
A simplified grading system for trachoma was published by the World Health 
Organization (WHO) in 1987. Intended for use by non-specialist personnel working at 
community level, the system includes five signs, each of which can be present or absent 
in any eye: (i) trachomatous trichiasis; (ii) corneal opacity; (iii) trachomatous 
inflammation—follicular; (iv) trachomatous inflammation—intense; and (v) trachomatous 
scarring. Though neither perfectly sensitive nor perfectly specific for trachoma, these 
signs have been essential tools for identifying populations that need interventions to 
eliminate trachoma as a public health problem. In 2018, at WHO’s 4th Global Scientific 
Meeting on Trachoma, the definition of one of the signs, trachomatous trichiasis, was 
amended to exclude trichiasis that affects only the lower eyelid. This paper presents the 
amended system, updates its presentation, offers notes on its use and identifies areas 
of ongoing debate. 
Introduction 
Trachoma is the most important infectious cause of blindness.1 Repeated conjunctival infection2 
with particular strains of Chlamydia trachomatis results,3–5 in some people, in conjunctival 
scarring, trichiasis and corneal opacity. The disease is strongly linked to poverty.6 In March 
2019, 142 million people globally were at risk.7 
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At the population level, trachoma may be hyperendemic, severe and blinding; or less 
severe and non-blinding.8 Models suggest that more than 150 episodes of C. trachomatis 
infection are required to develop trichiasis from trachoma;9 immune responses to infection are 
critical in the pathogenetic pathway.10,11 Populations therefore presumably transition from having 
blinding to non-blinding disease through reductions in intensity of ocular C. trachomatis 
transmission. These reductions in transmission can occur through general socioeconomic 
improvement12,13 or specific implementation of the antibiotics, facial cleanliness and 
environmental improvement components of the SAFE strategy for trachoma elimination;14 the S 
of SAFE representing surgery for trichiasis,15 which does not alter transmission. However, C. 
trachomatis transmission intensity16,17 would be extremely difficult to measure directly. In 
contrast, conjunctival inflammatory responses to infection11 can be observed by examination of 
the conjunctiva under low-power magnification. Because of this, and because the vision-
impairing effects of trachoma are manifest through macroscopic changes in the eyelid and 
cornea, assessment of the public health impact of trachoma is carried out through detection of 
physical signs of disease.18 
In 1987, the World Health Organization (WHO) published the simplified trachoma 
grading system to provide a standardized method for non-specialist personnel to undertake such 
assessments.19 The system, which was field-tested in three countries,19,20 has five signs: 
(i) trachomatous trichiasis; (ii) corneal opacity; (iii) trachomatous inflammation—follicular; 
(iv) trachomatous inflammation—intense; and (v) trachomatous scarring.19 Trachomatous 
inflammation—follicular and trachomatous inflammation—intense are signs of active 
(inflammatory) trachoma, usually associated with conjunctival C. trachomatis infection.21 The 
signs of the simplified system have been used to complete baseline mapping of trachoma in 
suspected endemic districts worldwide,22,23 to assess the impact of interventions in both 
research24,25 and programme26,27 contexts, and to establish criteria for elimination of trachoma as 
a public health problem.28 
During recent programmatic scale-up and transition of countries through the validation 
process,29 technical questions have arisen about the use of some of the simplified system’s signs. 
In November 2018, WHO convened the 4th Global Scientific Meeting on Trachoma in part to 
address those questions. In particular, the meeting considered whether the prevalence of 
trachomatous inflammation—follicular in 1–9-year-olds remains the best way for programmes to 
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determine whether ocular C. trachomatis transmission intensity has been sufficiently reduced to 
minimize the risk of future trachomatous blindness. Also considered was whether the definition 
of trachomatous trichiasis could be improved to better differentiate trachomatous from non-
trachomatous trichiasis. As a consequence, the definition of trachomatous trichiasis was 
amended to exclude trichiasis affecting only the lower eyelid, on the basis that such cases are 
unlikely to be due to trachoma and that labelling them as trachomatous trichiasis constitutes 
potential misclassification.30 
In the current paper we set out the simplified system including that amendment, and 
revise the presentation of the system to help users better understand and more consistently apply 
the definitions. We discuss the continuing programmatic dependence on the prevalence of 
trachomatous inflammation—follicular as a clinical proxy for current ocular C. trachomatis 
transmission intensity. Finally, we outline other topics for continuing research and reflection. 
Inevitably, this paper draws heavily from the original article.19 
Method of examination 
The examiner should always use clean hands (by, for example, applying alcohol-based hand 
sanitizer), binocular loupes (magnification × 2.5) and adequate lighting (either sunlight or a 
torch). Although sunlight provides the best illumination for examining the conjunctiva, it is 
better to examine for trachomatous trichiasis indoors because of the photophobia that patients 
with trichiasis experience. An examination station on the edge of a shaded area can be ideal, but 
survey teams typically move house-to-house. When examining the conjunctiva outdoors, it is 
important to orient the person being examined so that light from the sun passes across the 
examiner’s shoulder onto the person’s face. When using a torch, care should be taken not to 
contaminate it with fingers that have been in contact with the person’s skin or eye. An assistant 
can help to hold and reassure children while they are examined.31 
To help ensure that abnormal findings are correctly recorded, the right eye should always 
be examined first, then the left eye. To assess for the presence or absence of each of the signs of 
the system, the structures to be examined in each eye are, in order: the upper eyelid margin and 
its eyelashes, then the cornea, then the upper tarsal conjunctiva (the conjunctiva lining the upper 
eyelid). 
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To examine for trachomatous trichiasis, with the examinee’s eye open and the eyelid in 
its resting state, the examiner should adopt a position so that his or her eyes are below the 
horizontal plane through the person’s eye. Light should be shone from below then from the 
temporal side while the examiner inspects the upper eyelid eyelashes to see if any eyelashes 
touch the eyeball. The examinee should be asked to move their eyes to the extremes of gaze on 
either side to see if the upper eyelid eyelashes move with the eyeball. The upper eyelid should 
then be gently lifted upwards slightly to expose the eyelid margin and lift any in-turned 
eyelashes out of the tear film. The eyelid margin should be inspected for empty eyelash follicles 
or broken eyelash shafts, which may indicate recent epilation. 
The cornea should be inspected for opacities. 
The eyelid is everted and the conjunctiva inspected for follicles, pronounced 
inflammatory thickening, and scarring. When examining for follicles, only those found within 
the central part of the upper tarsal conjunctiva (Fig. 1) are considered significant.19 
Appearance of the normal eye 
The appearance of the normal eye when examined for trachoma is as follows (Fig. 2): (i) no 
eyelashes touch the eyeball and there is no evidence of recent epilation; (ii) the cornea is smooth, 
transparent and avascular; and (iii) the upper tarsal conjunctiva is smooth, thin and transparent. 
Beneath the whole area of the upper tarsal conjunctiva, there are large deep-lying blood vessels 
that mainly run vertically from the upper and lower edges of the tarsal plate.19 
Amended simplified grading system 
The amended simplified grading system includes five signs, each of which can be present or 
absent. A sign must be clearly seen to be considered present. If the examiner is in doubt, a sign 
should be recorded as being absent. The list below presents the definitions of the signs. 
Amendments from the original grading system19 are shown in italics (Fig. 3). 
Trachomatous trichiasis 
At least one eyelash from the upper eyelid touches the eyeball, or evidence of recent epilation of 
in-turned eyelashes from the upper eyelid.  
Corneal opacity 
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Easily visible corneal opacity that is so dense that at least part of the pupil margin is blurred 
when viewed through the opacity. This definition is intended to detect corneal opacities that 
cause significant visual impairment. In individuals with corneal opacity, visual acuity should be 
measured, if possible. 
Trachomatous inflammation—follicular 
The presence of five or more follicles, each at least 0.5 mm in diameter, in the central part of the 
upper tarsal conjunctiva. Follicles are round lumps or spots that lie beneath more superficial 
epithelium and are paler than the surrounding tissue. Care should be taken to distinguish follicles 
from small scars, conjunctival concretions, cysts and giant papillae (please see below).  
Trachomatous inflammation—intense 
Pronounced inflammatory thickening of the upper tarsal conjunctiva that obscures more than half 
of the normal deep tarsal vessels. The key feature of trachomatous inflammation—intense is 
pronounced inflammatory thickening, which is defined as being present when more than half of 
the normal deep tarsal vessels are not visible because they are obscured by inflammatory 
infiltration. The tarsal conjunctiva appears red, rough and thickened, due to diffuse infiltration, 
oedema and enlargement of vascular tufts (papillary hypertrophy). There are also usually 
numerous follicles, which may be partially or totally obscured by the thickened conjunctiva. 
Inflammatory thickening and opacification of the conjunctiva should not be confused with that 
caused by scarring, which can manifest as diffuse fibrosis or formation of a fibrovascular 
membrane. 
Trachomatous scarring 
The presence of easily visible scarring in the upper tarsal conjunctiva. Scars are white lines, 
bands, or sheets in the upper tarsal conjunctiva. Characteristically, the scars are glistening and 
fibrous in appearance, with straight, angular or feathered edges. Scarring, especially diffuse 
fibrosis, may obscure tarsal blood vessels, but this must not be confused with diffuse 
inflammatory thickening. 
Less florid presentations 
Some eyes do not have signs of trachoma as defined above but are nevertheless abnormal. For 
example, the upper tarsal conjunctiva may have any of the following: from one to four central 
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follicles each at least 0.5 mm in diameter; five or more central follicles but fewer than five that 
are at least 0.5 mm in diameter; inflammatory thickening that does not obscure half of the deep 
tarsal vessels; more than half of the deep tarsal vessels obscured by something other than 
pronounced inflammatory thickening.  
Eyes should not be recorded as having a sign whose definition they do not meet. Graders 
should be confident that this is not equivalent to saying that they are normal eyes. 
Other abnormalities 
Other abnormalities that can be mistaken for follicles are illustrated in Fig. 4. Scars have angular 
borders with sharp corners, whereas follicles have rounded edges that are not sharply defined. 
Concretions are yellow or white masses with clear-cut edges. Cysts are clear bubbles in the 
conjunctiva. Giant papillae are protuberances of the conjunctival epithelium that are greater 
than 1 mm in diameter; they characteristically have flattened tops and are responsible for more 
pronounced elevation of the epithelial surface than occurs with follicles. 
Discussion 
Clear definitions are a prerequisite for collecting good data. Broad consensus on the relevance of 
the data being collected increases the likelihood that the outputs of the data collection process 
will be accepted and applied.32 The amendment to the definition of trachomatous trichiasis 
introduced in this version of the WHO simplified trachoma grading system has been endorsed by 
WHO. This endorsement follows the consensus, reached within an expert panel,30 that 
trachomatous trichiasis characteristically affects upper eyelids, with additional involvement of 
lower eyelids in a minority of people. Involutional entropion, an age-related condition, does not 
affect upper eyelids. Excluding lower-eyelid-only disease will avoid trichiasis caused by 
involutional entropion being misinterpreted as trachomatous trichiasis. 
In addition to recording the amended definition of trachomatous trichiasis, we have 
attempted in this paper to aid users of the simplified system through changes that streamline and 
clarify its presentation. Our changes are in line with other recent efforts to improve quality 
control and quality assurance in the assessment of trachoma for public health purposes.33 
First, we have separated the description of the normal eye from the presentation of the 
signs of the system. In the original paper, under the heading “The grading system and its use,” 
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the first subheading was “Normal conjunctiva” followed by subheadings for each of the five 
signs.19 This layout may have encouraged the (unfortunately frequent) misunderstandings that 
normal conjunctiva and the five signs of the system are points along a continuum of disease, 
mutually exclusive, or an all-encompassing classification system. Trachoma involves repeated 
cycles of conjunctival C. trachomatis infection, active trachoma and resolution, driving an 
underlying scarring process.2,9 An eye may have any combination of signs present at the same 
time. And an eye may demonstrate evidence of active trachoma that is insufficiently florid to 
meet the definition of either trachomatous inflammation—follicular or trachomatous 
inflammation—intense, trachomatous conjunctival scar that is insufficiently severe to meet the 
definition of trachomatous scarring, or a trachomatous corneal scar that is insufficiently dense or 
too close to the limbus to meet the definition of corneal opacity. There may also be signs of 
trachoma not mentioned in the system,34 or abnormalities unrelated to trachoma. 
Second, we have tried to ensure that all the critical elements of the definition of each sign 
are included in the formal definition statement. For example, for trachomatous inflammation—
follicular, we have included in the statement the requirements for follicles to be greater than or 
equal to 0.5 mm in diameter and located in the central part of the upper tarsal conjunctiva. 
Previously the statement read, “the presence of five or more follicles in the upper tarsal 
conjunctiva,” with notes on the area to be examined and the minimum follicle size included 
elsewhere in the text of the paper.19 These refinements should facilitate use of the grading 
system. 
Third, we have placed the definitions for trachomatous trichiasis and corneal opacity 
above those for trachomatous inflammation—follicular, trachomatous inflammation—intense 
and trachomatous scarring. When conducting a physical examination, the general principle is to 
look before touching, and to undertake less invasive before more invasive examination steps. 
Examination for the five signs of the trachoma grading system, therefore, should commence with 
examination for trachomatous trichiasis, then examination for corneal opacity, then lid eversion 
and examination of the conjunctiva. This sequence was recommended within the text of the 
original paper, but the order in which the signs were presented appeared to contradict it.19 The 
revised order will also hopefully help to counteract the common but incorrect impression that the 
signs listed in the simplified grading system develop in inevitable sequential order after 
acquisition of ocular C. trachomatis infection. 
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Fourth, unlike the original paper, the new presentation of the grading system does not 
support discretionary use of “loupes of higher magnification or a slit lamp.”19 The rationale for 
removing this option is straightforward. Slit lamps are rarely available for field use in trachoma 
surveys. Standardization of examination methods is important to maximize their 
reproducibility.33 Corneal opacity and conjunctival scarring must be easily visible to be graded as 
corneal opacity and trachomatous scarring, respectively. If magnification and illumination differ 
between examiners or between time points, what is easily visible in one instance may not be 
easily visible in another. 
It is worth emphasizing here that the grading system was designed, and is still principally 
intended, for non-specialist health personnel working in the community.19 The grading system is 
an essential tool for population-based surveys, where large numbers of graders need to be trained 
to generate accurate data on trachomatous trichiasis and trachomatous inflammation—follicular, 
the signs most directly linked to programmatic action and which are used in the criteria for the 
elimination of trachoma as a public health problem.28 As noted above, many individuals have 
clear evidence of trachoma but do not have disease meeting the definition for any of the five 
signs codified here. More detailed systems, such as the modified WHO FPC system (follicles, 
papillary hypertrophy and diffuse infiltration, conjunctival scarring),34 may therefore be more 
suitable for other applications, particularly research studies.35 Use of a more detailed grading 
system may be important in studies using highly sophisticated laboratory tests, such as 
polymerase chain reaction testing, in which the results of the tests are compared with the 
presence of signs at the individual level.36,37 
Research into and discussion of further refinement of the simplified trachoma grading 
system would be welcome. For trachomatous trichiasis, we believe that two components of the 
amended definition deserve ongoing attention. 
First, “evidence of recent removal of in-turned eyelashes” qualifies an eye to be 
diagnosed with trachomatous trichiasis. This definition implies that all epilated eyelashes were 
in-turned, although data suggest that field graders may have difficulty determining whether or 
not an epilated eyelash was in-turned before it was pulled out.38 The meaning of “recent” within 
this context has never been defined, but has been interpreted by users of the system as the 
appearance of broken eyelashes or empty eyelash follicles. 
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Second, data are needed to determine whether restriction of diagnostic focus to the upper 
eyelid is sufficient to exclude, as intended, most cases of non-trachomatous trichiasis. This point 
is essential for trachoma programmes, which for the purposes of validating elimination of 
trachoma as a public health problem must demonstrate the trachomatous trichiasis prevalence 
unknown to the health system in individuals aged 15 years and older is less than 0.2%. Trichiasis 
can be caused by processes other than trachoma, and the background prevalence of non-
trachomatous trichiasis is usually not known for any particular area. There is ongoing research 
into whether the presence of trachomatous scarring (or conjunctival scar more generally) should 
be a requirement for trichiasis to be considered due to trachoma, as discussed at the 2nd Global 
Scientific Meeting on Trachomatous Trichiasis.39 Such an approach would be consistent with 
earlier, more detailed WHO trachoma grading systems.40,41 These systems included trichiasis 
wholly within the diagnostic domains for conjunctival scarring, implying that, in trachoma, 
trichiasis was exclusively an end-stage feature of a scarred eyelid. Similarly, the original 
presentation of the simplified system noted that, “for the potentially disabling, irreversible 
lesions, trachomatous scarring may represent all levels of conjunctival scarring, whereas the 
coding of trachomatous trichiasis corresponds to more severe cases.”19 Some authorities, 
however, are concerned about the repeatability, sensitivity or specificity of the diagnosis of 
trachomatous scarring.30 An alternative algorithm might involve reference, at individual or 
evaluation unit level, to the presence of corneal pannus at the upper pole of the limbus or to 
Herbert’s pits,42 each of which is considered highly specific for trachoma. Unfortunately, these 
signs are also likely to be imperfectly sensitive. 
For trachomatous inflammation—follicular, the size of the follicles matters, although 
there are no experimental data to show that follicles of different sizes produce differential risk of 
scarring. The requirement that follicles should be at least 0.5 mm in diameter was introduced 
more than three decades ago. The aim of the change then was to improve inter-observer 
agreement, which had been suboptimal when using a draft definition of trachomatous 
inflammation—follicular in initial tests of the system.19 Unfortunately, the line drawing of 
trachomatous inflammation—follicular that was included in the original simplified system 
paper19 displayed follicles which (when calibrated with reference to photographs of the everted 
conjunctivae of children from Ethiopia and Niger) have a diameter 20% smaller than 0.5 mm.43 
We have omitted the diagram from this paper. Follicle size guides44 have recently been 
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introduced to help graders to consistently diagnose the presence or absence of trachomatous 
inflammation—follicular according to the agreed definition. 
A separate concern for trachomatous inflammation—follicular in some settings is the 
extent to which its prevalence may give a false impression of ocular C. trachomatis infection or 
the intensity of ocular C. trachomatis transmission.45–50 More investigation on this is needed.30 
The global prevalence of trachoma is progressively declining,7 due to a combination of 
intensive programmatic intervention, improvements in living standards and better data. The 
amendments to the simplified grading system described here should help ensure that it continues 
to be useful for estimating the burden of trachoma in population-based surveys, and for 
evaluating the impact of control efforts over time.19 
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Fig. 1. Outline sketch of an everted upper eyelid 
 
 
Note: The drawing shows the area of the tarsal conjunctiva (shaded) to be examined for follicles. 
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Fig. 2a. A normal eye - eyelid margin and cornea 
 
Note: Credit to Sandip Das Sanyam for the eyelid margin and cornea photo. 
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Fig. 2b. A normal eye - upper tarsal conjunctiva 
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Fig. 3. The five signs of the World Health Organization simplified trachoma grading system 
     
a. Trachomatous trichiasis b. Trachomatous trichiasis, manifest    c. Corneal opacity 
through evidence of recent epilation of  
in-turned eyelashes from the upper eyelid 
    
d. Trachomatous inflammation—follicular e. Trachomatous inflammation—intense  f. Trachomatous scarring 
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Fig. 4. Abnormalities of the conjunctiva that are sometimes mistaken for follicles  
      
a. Scars       b. Concretions 
 
  
c. Cysts       d. Giant papillae 
